GSK's Hal Barron buys a $250M stake in George Scangos' Vir and makes a beeline to the clinic with Covid-19 antibodies
GlaxoSmithKline is diving straight into the swirling waters of Covid-19 R&D work, and investing $250 million to grab a chunk of equity in one of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
